Additionally, an intriguing pre-clinical observation made in immune-competent mice challenged with melanoma demonstrates that acquired resistance to immune checkpoint blockade is reversed by inhibiting JAK1/JAK2 signaling48. Here, JAK2 is linked to melanoma.